TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25619124
Drug: Tamoxifen 10mg
Normalized name: TAMOXIFEN 10MG/5ML SOLN,ORAL
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 10mg daily for 12 weeks
Study: 23933145
Drug: Nicotine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (4 mg) given as nicotine gum
Study: 21035560
Drug: Salmeterol 25
Normalized name: fluticasone-salmeterol 250 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 25 μg
Study: 20856830
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 μg
Study: 18302293
Drug: Prophylactic lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prophylactic lamivudine treatment
Study: 12697482
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCBPA) with a mixture of 1% lidocaine and 0.25% bupivacaine, basal infusion of 2 ml/h, bolus dose of 3 ml, lockout time of 45 min.
Study: 10321416
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg once daily for 4 weeks, followed by 16 mg once daily for 4 weeks
Study: 10321416
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 8 mg twice daily for 4 weeks
Study: 10321416
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (once and twice daily)
Study: 10321416
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (once daily)
Study: 7050717
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus chemotherapy with dacarbazine
Study: 26178726
Drug: C8-dietary oil
Normalized name: C8:0
DrugBank: Caprylic acid (DB04519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C8-dietary oil (13.15 g)
Study: 26178726
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (19 g)
Study: 26178726
Drug: Tributyrin (6.53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tributyrin (6.53 g)
Study: 24646528
Drug: Amoxicillin/clavulanate (antibiotics)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (antibiotics)
Study: 10695392
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose prednisolone (1.0 mg/kg/day)
Study: 4028963
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine (E) 0.3 mg sub-Q q20min (max 0.9 mg)
Study: 4028963
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine (E)
Study: 30535090
Drug: Sucralose consumption
Normalized name: Sucralose
DrugBank: Sucralose (DB15049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose consumption (15% of Acceptable Daily Intake every day for 14 days)
Study: 16119515
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg tablets (test formulation)
Study: 16119515
Drug: Klaricid (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klaricid (reference formulation)
Study: 8055292
Drug: Unilateral electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral electroconvulsive therapy (U‐ECT) with nondominant long-distance parietotemporal electrode placement
Study: 8055292
Drug: Bilateral bitemporal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral bitemporal electroconvulsive therapy (ECT)
Study: 3341801
Drug: Potent topically
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent topically administered steroids
Study: 4177135
Drug: Rh-immune globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rh-immune globulin administered at delivery
Study: 11244765
Drug: roxatidine acetate
Normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine acetate hydrochloride 150 mg
Study: 29682294
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard treatment)
Study: 23469662
Drug: Transperineal ultrasonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transperineal ultrasonic therapy
Study: 14665549
Drug: Alfentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 15 micro g kg(‐1) h(‐1) + Propofol 6 mg kg(‐1) h(‐1)
Study: 14665549
Drug: Alfentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 15 micro g kg(‐1) h(‐1) + Propofol 3 mg kg(‐1) h(‐1)
Study: 14665549
Drug: Vertex‐inion electrode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertex‐inion electrode site after 30 min of propofol infusion
Study: 8238130
Drug: Antibiotics (ampicillin‐amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (ampicillin‐amoxicillin and erythromycin)
Study: 3120568
Drug: High nitrogen
Normalized name: Isosource High Nitrogen Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High nitrogen diet (366 mg N/(kg.d))
Study: 3120568
Drug: Low nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low nitrogen diet (191 mg N/(kg.d))
Study: 24989946
Drug: Abediterol 10
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 10 µg
Study: 24989946
Drug: Abediterol 25
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 25 µg
Study: 24989946
Drug: Abediterol 50
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 50 µg
Study: 1961960
Drug: Thiopental for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental for intravenous induction with oxygen/nitrous oxide (30/70%) for maintenance (group I)
Study: 7013978
Drug: BCNU or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU or methyl-CCNU chemotherapy without radiotherapy (Category A)
Study: 7013978
Drug: Whole-brain radiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiation treatment (6000 rad) with surgery (Category B)
Study: 15385223
Drug: Disulfiram (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (200 mg daily)
Study: 24117666
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy (mailed letters emphasizing harmful effects of alcohol)
Study: 19950569
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Aspart (IAsp) with NPH
Study: 19950569
Drug: Human Insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Insulin (HI) with NPH
Study: 2257065
Drug: TXA2 synthesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA2 synthesis inhibitor, anisodamine
Study: 25781977
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose (800 mg albendazole) annually for 24 months (H1)
Study: 20095375
Drug: Interferon alpha‐2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b, 3 million IU, administered rectally on chemotherapy days (twice weekly) for 4 months or more
Study: 17119538
Drug: Farampator (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farampator (500 mg)
Study: 9150314
Drug: IL-10 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 treatment in co-cultures with AMs from healthy volunteers
Study: 9150314
Drug: IL-10 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 treatment in co-cultures with AMs from patients with IPF
Study: 28455085
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen 1000 mg every 8 hours for 48 hours (total of 6 doses)
Study: 21164304
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (IVS)
Study: 23192781
Drug: Gadoxetate disodium
Normalized name: Gadoxetate Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoxetate disodium (10 mL, n = 97; 8 mL, n = 1; 16 mL, n = 1)
Study: 23192781
Drug: Gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobenate dimeglumine (0.1 mmol per kilogram of body weight, maximum dose, 20 mL)
Study: 18503218
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (10 mg/kg orally, 3 times per week for 12 months)
Study: 15904591
Drug: Intraincisional (II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraincisional (II) instillation of 25 mg of bupivacaine
Study: 12580839
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100-150 mg/day for five days starting from day 2 of the cycle and 150 IU of hMG/day on days 6-10, GnRH antagonist (Centrorelix) 0.25 mg/day started when the leading follicle reached 16 mm in the absence of an LH surge
Study: 498828
Drug: Quinidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (200 mg every six hours)
Study: 28511669
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg once daily for 12 months
Study: 19289710
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray, 200 microg once daily
Study: 17021664
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (laser instrument switched off) applied over the same protocol as the intervention group
Study: 11515948
Drug: Labial infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labial infiltration of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Study: 11515948
Drug: Labial infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labial infiltration of 1.8 mL of 2% lidocaine with 1:50,000 epinephrine
Study: 8908388
Drug: UAE (Urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: UAE (Urinary Albumin Excretion)
Study: 27865590
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection (100 units of Botox)
Study: 21247664
Drug: Aquaphor Healing
Normalized name: Aquaphor Healing
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquaphor Healing Ointment (AHO)
Study: 21651908
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sildenafil citrate
Study: 12722035
Drug: Dual-dialyzer therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-dialyzer therapy
Study: 8528039
Drug: Active 22
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active 22 mg nicotine patches
Study: 7324833
Drug: buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine (0.3 mg)
Study: 1675119
Drug: oxymorphone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxymorphone (1 mg)
Study: 23424061
Drug: Continuous theta
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous theta burst stimulation (cTBS), 5 daily sessions
Study: 12761725
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy
Study: 15376398
Drug: Jia Wei
Normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jia Wei Si Jun Zi Tang (JWSJZT) + regular protective therapy
Study: 15376398
Drug: Regular protective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular protective therapy
Study: 9356538
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (2.1 g/kg)
Study: 9356538
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.7 g/kg)
Study: 31668666
Drug: Intraosseous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraosseous dexamethasone injection (4 mg)
Study: 31668666
Drug: Submucosal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Submucosal dexamethasone injection
Study: 31668666
Drug: Both techniques
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both techniques of dexamethasone injection
Study: 21359646
Drug: Oral rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxaban 10 mg once daily for 35 ± 4 days
Study: 10709776
Drug: Fluconazole (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (≥ 200 mg/day)
Study: 14668578
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg twice daily
Study: 28628884
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (specifics not provided)
Study: 25419594
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TB and SBA
Study: 8567141
Drug: Ultrasonographic monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonographic monitoring of preoperative chemotherapy
Study: 2560470
Drug: CY 216
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CY 216 (7,500 anti-Xa units I.C. daily subcutaneous injection)
Study: 28234826
Drug: Round silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Round silicone implant
Study: 28234826
Drug: Both anatomical
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both anatomical and round implants
Study: 21150631
Drug: Caudal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caudal clonidine 1 μg kg⁻¹ with 0.25% bupivacaine (0.75 ml kg⁻¹)
Study: 6507309
Drug: Pindolol (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (small dose)
Study: 6507309
Drug: Pindolol (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (large dose)
Study: 24717460
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapy commencement ≥ 46.0 hours
Study: 21952978
Drug: Tofacitinib 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 3 mg twice a day
Study: 23294500
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg twice a day
Study: 21952978
Drug: Tofacitinib 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 15 mg twice a day
Study: 10989239
Drug: Lumbar spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar spine BMD greater than 1.20 g/cm(2) (or 2.5 S.D. above the mean)
Study: 10989239
Drug: Each 0.1
Normalized name: PEACH 0.1 g in 1 mL INTRADERMAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 0.1 g/cm(2) increase in lumbar spine BMD
Study: 10989239
Drug: Each 0.1
Normalized name: PEACH 0.1 g in 1 mL INTRADERMAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 0.1 g/cm(2) increase in femoral neck BMD
Study: 10989239
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy in osteoporotic women
Study: 27165014
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg
Study: 9411906
Drug: Amitriptyline 10
Normalized name: amitriptyline 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 10 mg
Study: 3397523
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg
Study: 1428304
Drug: Cyclobenzaprine (C)
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclobenzaprine (C) 10 mg
Study: 1428304
Drug: Cyclobenzaprine (C)
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclobenzaprine (C) 10 mg plus Ibuprofen (I) 600 mg
Study: 2413307
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg i.v.)
Study: 3935458
Drug: Sulpiride (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (25 mg i.v.)
Study: 3935458
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg i.v.)
Study: 31757206
Drug: Doxapram 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 50 mg
Study: 29134633
Drug: AZD1419 (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1419 (inhaled TLR9 agonist)
Study: 27035595
Drug: Coffee with
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee with 20% milk (175 ml)
Study: 27035595
Drug: Coffee with
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee with 50% milk (175 ml)
Study: 21147688
Drug: Odanacatib 5
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 5 mg daily for 4 weeks
Study: 21147688
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) 4 mg I.V. once at study initiation
Study: 17650211
Drug: Synbiotic milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic milk (Lactobacillus acidophilus strain 74‐2, 10(7) CFU ml(‐1), Bifidobacterium lactis strain 420, 10(7) CFU ml(‐1), 2% inulin) consumed for 4 weeks at 500 ml day(‐1)
Study: 17650211
Drug: Placebo (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2% skimmed milk) consumed for 4 weeks at 500 ml day(‐1)
Study: 16510462
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (medical and surgical)
Study: 14634938
Drug: Triple-injection axillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-injection axillary brachial plexus block (group A)
Study: 10783203
Drug: Streptokinase thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase thrombolytic therapy
Study: 4044777
Drug: 20 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms/day estradiol infusion
Study: 4044777
Drug: 90 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 micrograms/day estradiol infusion
Study: 31848172
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid injection followed by balloon dilatation
Study: 29063390
Drug: 2-year treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-year treatment group (2YG, N = 112)
Study: 29063390
Drug: 3-or-more-year treatment
Normalized name: Sore No More 3 % / 3 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-or-more-year treatment group (3YG, N = 110)
Study: 24284387
Drug: 8-12-week treadmill
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-12-week treadmill exercise program (target lactate 2.0±0.5 mmol l(‐1))
Study: 16118817
Drug: Insecticide spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insecticide spray
Study: 8847032
Drug: 20mg Omeprazole
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg Omeprazole tid + 500mg Amoxicillin qid
Study: 8847032
Drug: 20mg Omeprazole
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg Omeprazole qid + 500mg Amoxicillin qid
Study: 28681650
Drug: E6011 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 200 mg
Study: 29746133
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation X1
Study: 29746133
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation Y1
Study: 24062178
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (5th dose)
Study: 24062178
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (MenB vaccine-naive participants receiving 4CMenB)
Study: 14600189
Drug: Long-acting beta2-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta2-agonists
Study: 14600189
Drug: Domiciliary oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary oxygen therapy
Study: 8977745
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day carbimazole
Study: 27654971
Drug: AZD8931 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 20 mg
Study: 27654971
Drug: AZD8931 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 40 mg
Study: 20831889
Drug: Oral-appliance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-appliance therapy
Study: 16911345
Drug: Oxcarbazepine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (1200 mg/day)
Study: 16002074
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg
Study: 9129477
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement (1000 mg supplemental Ca/d as calcium citrate malate)
Study: 30715100
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure treatment goal
Study: 28969626
Drug: AyuFlex2 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AyuFlex2 (500 mg twice daily)